Obesity and inflammatory bowel disease (IBD) are systemic inflammatory disorders that predispose to arterial and venous thrombosis through similar prothrombotic mechanisms.
Abstract
Obesity and inflammatory bowel disease (IBD) are systemic inflammatory disorders that predispose to arterial and venous thrombosis through similar prothrombotic mechanisms.
Obesity and IBD are chronic risk factors that lead to a persistently elevated risk of thrombosis, although the thrombotic risk with IBD appears to wax and wane with disease severity. Because of a lack of high quality evidence to guide management decisions, approaches to the prevention and treatment of thrombosis in patients with obesity or IBD are based on extrapolation from general guidelines for antithrombotic therapy. Obesity alters the pharmacokinetics of some anticoagulant drugs, and IBD patients present the added management challenge of having a high risk of gastrointestinal bleeding while taking anticoagulants. An indefinite duration of anticoagulant therapy is often recommended for obese or IBD patients with unprovoked venous thromboembolism unless there is a high risk of bleeding, although more data and better biomarkers are needed to determine if anticoagulation can be safely stopped in a subset of IBD patients during remission of active disease. Most patients with obesity or IBD require thromboprophylaxis in conjunction with hospitalization or surgery, with adjustment of anticoagulant dosing in patients with severe obesity.
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Inflammation as a trigger of thrombosis
It has long been recognized that inflammation can activate coagulation systems, leading to consumption coagulopathy, thrombosis, and tissue injury. The classic paradigm of inflammationtriggered coagulopathy is bacterial sepsis, in which the acute systemic inflammatory response to infection leads to endothelial injury and expression of tissue factor, a potent initiator of coagulation. 1 The resultant activation and consumption of coagulation factors and platelets, along with impaired fibrinolysis, disruption of endothelial barrier function, and loss of physiological antithrombotic factors such as thrombomodulin, 2 creates a clinical situation in which the patient may be at risk not only for hemorrhage but also for arterial, venous, or microvascular thrombosis. Acute, fulminant coagulopathy also can be triggered by inflammatory processes driven by non-infectious conditions such as cancer, trauma, severe burns, or complications of pregnancy.
Thrombosis is also a relatively common complication of conditions associated with chronic inflammation, such as obesity, inflammatory bowel disease (IBD), and other autoimmune disorders. 3, 4 The hematology consultant is often asked to provide recommendations regarding the prevention and management of thrombosis in such patients for whom evidence-based guidelines may not be available. This chapter will update the management of adult patients at risk for thrombosis due to obesity or IBD as exemplars of chronic prothrombotic inflammatory conditions.
Obesity
The World Health Organization estimates that the global prevalence of obesity has more than doubled since 1980. 5 In 2008, more than 1.4 billion adults were overweight (body mass index (BMI) ≥ 25 kg/m 2 ) and nearly 500 million were obese (BMI ≥ 30). 5 In 2010, the prevalence of For personal use only. on . by guest www.bloodjournal.org From 4 obesity in the United States had reached 35% among adults and 20% among children 6 to 11 years of age. 6 An abundance of clinical and epidemiological evidence has established that obesity is a risk factor for arterial and venous thrombosis. Obesity is a predictor of incident myocardial infarction independent of gender, age, or ethnicity. 7 Obesity also is a risk factor for ischemic stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) in both men and women. 8, 9 In a metaanalysis of the influence of obesity on the risk of a first episode of venous thromboembolism (VTE), Ageno et al. 10 estimated an overall odds ratio for VTE of 2.3 (95% CI, 1.7 to 3.2) ( Figure   1A ), which is similar to other established risk factors for first VTE such as heterozygous factor V Leiden and estrogen therapy but lower than major risk factors such as surgery, hospitalization, cancer, or major trauma. 4 Analysis of data from the Atherosclerosis Risk in Communities (ARIC) and the Cardiovascular Health Study (CHS) generated a similar hazard ratio of 2.2 for VTE among patients with obesity (BMI ≥ 30) and a slightly higher hazard ratio of 2.7 for patients with severe (class III) obesity (BMI ≥ 40). 11 Obesity also is a risk factor for recurrent VTE. Eichinger et al. found that the probability of recurrent VTE was significantly higher among patients with obesity compared with patients of normal BMI, with an estimated a hazard ratio of 1.6. 12 This degree of risk is strikingly similar to that of other risk factors for recurrent VTE 13 ( Figure 2 ). The impact of obesity on risk of recurrent VTE may be even higher in women than men. Rodger et al. estimated a relative risk of 2.3 for recurrent VTE in women with obesity (BMI ≥ 30) after a first episode of unprovoked VTE.
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Mechanisms of thrombosis in obesity
The major mechanisms thought to be responsible for obesity-associated thrombosis are chronic inflammation, impaired fibrinolysis, and clinical factors such as immobility, obstructive sleep thrombin generation, and enhanced platelet activation. 16 Finally, inflammation in obesity is associated with impairment of fibrinolysis due to a marked increase in the expression of plasminogen activator inhibitor-1 (PAI-1).
Prevention and management of thrombosis in obese patients
Other than weight loss, which reverses many of the prothrombotic metabolic effects of obesity, 17 no obesity-specific therapeutic approaches to prevent or treat thrombosis are available.
Treatment decisions in obese patients are complicated by the fact that relatively few patients with severe obesity were included in the major clinical trials investigating antithrombotic drugs.
Because of a lack of high grade evidence to support specific recommendations for obese patients, general recommendations for the prevention and treatment of thrombosis in obese patients are very similar to those in lean patients. Although obese individuals have an elevated relative risk for VTE, the absolute risk is not high enough to justify the routine use of long-term anticoagulant therapy for primary prevention. Patients should be advised to avoid lifestyle factors that might compound thrombotic risk, such as cigarette smoking and inactivity. Acutely ill obese patients at high risk for thrombosis (e.g. Padua prediction score ≥ 4) 18 should receive anticoagulant thromboprophylaxis in conjunction with hospitalization unless they are at high risk of bleeding. 19 Most obese patients undergoing major surgery have at least a moderate risk (modified Caprini score ≥ 3) for VTE, 20 and should receive anticoagulant and/or mechanical thromboprophylaxis depending on the risk of bleeding. 21 For obese patients with provoked VTE, the recommended duration of anticoagulant therapy is similar to that in patients without obesity (typically anticoagulant therapy for a minimum of 3 months). 22 For obese patients with unprovoked VTE, indefinite anticoagulant therapy is often recommended unless there is a high risk of bleeding. Obese patients also may have an elevated risk of post-thrombotic syndrome, but the degree to which they might benefit from catheter-directed thrombolytic therapy is not known.
Pharmacology and dosing of anticoagulants in obese patients
The dosing of anticoagulants is inherently challenging in obese patients, especially for anticoagulants administered in fixed doses, such as low-molecular weight heparins (LMWHs) and fondaparinux when used for thromboprophylaxis, and the direct oral anticoagulants (DOACs).
For personal use only. on . by guest www.bloodjournal.org From Heparin. When used for therapeutic indications, unfractionated heparin dosing is initially weightbased (e.g. an initial bolus dose of 80 U/kg followed by 18 U/kg per hour as a continuous infusion) and the dose is adjusted using the activated partial thromboplastin time (aPTT).
Heparin has unpredictable bioavailability in obese patients, however, and patients with severe obesity may have altered weight-based heparin requirements. One recent retrospective cohort study found that critically ill patients who weighed greater than 165 kg required lower doses of heparin per kg of total body weight, whereas patients with true body weights from 105 to 164 kg had weight-based heparin requirements similar to nonobese patients. 23 When subcutaneously administered unfractionated heparin was used for thromboprophylaxis, a dosage of 7500 units three times daily was found to be more effective than standard dosing (5000 units two or three times daily) in preventing VTE and did not increase bleeding in patients with BMI ≥ 40.
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LMWH and fondaparinux. LMWHs and fondaparinux have more predictable bioavailability than unfractioned heparin, even in patients with obesity. In general, anticoagulant activity as measured by anti-Xa activity is increased to appropriate levels when enoxaparin, dalteparin, or tinzaparin are administered to obese patients in doses based on total body weight, without an excess of major bleeding, up to a weight of approximately 150 kg. 25 For therapeutic dosing of LMWHs, dosing based on total body weight is reliable for patients into the obese body weight range (BMI 30 to 39 or weight 100 to 150 kg), but data are sparse for heavier patients (BMI ≥ 40 or body weight > 150 kg). Although there is some disagreement whether or not to cap the dose of LMWHs for patients with a body weight above 150 kg, most guidelines recommend LMWH dosing based on total body weight, without capping, for the treatment of severely obese patients. 26 For personal use only. on . by guest www.bloodjournal.org From 8
As might be expected, for thromboprophylaxis with fixed-dose (not weight-adjusted) LMWHs, there is an inverse correlation between total body weight and anti-Xa levels in patients weighing up to 150 kg, which suggests that obese or severely obese patients may require higher fixed doses of LMWHs than lean patients. Most guidelines recommend increasing the prophylactic dose of LMWHs by 30 to 50% for patients with BMI ≥ 40, but these are low-grade recommendations largely based on expert opinion. Table 1 summarizes the University of Iowa institutional recommendations for dosing of enoxaparin when used for VTE prophylaxis in obese and severely obese patients. Anti-Xa monitoring and dosing based on anti-Xa levels might be expected to offer benefit for adult patients with severe obesity. However, validated anti-Xa target ranges for thromboprophylaxis are lacking, and current American College of Chest Physicians (ACCP) guidelines do not recommend routine coagulation monitoring for prophylactic dosing, even in obese patients. 25 This recommendation is supported by a recent systematic review of the Cochrane database, which concluded that routinely determining anti-Xa concentrations in obese patients to monitor the clinical effectiveness of LMWH is not warranted on the basis of the current evidence.
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Direct oral anticoagulants (DOACs). The anticoagulation landscape has changed dramatically in the last five years, driven by the approval and licensing of four DOACs: dabigatran, rivaroxaban, apixaban, and edoxaban. Dabigatran is a direct thrombin inhibitor, whereas rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. 28 The DOACs represent a major advance in oral anticoagulant therapy because (at least in non-obese patients) they can be administered in fixed doses without the need for laboratory monitoring. The DOACs are rapidly replacing warfarin as the anticoagulant of choice for many indications, including stroke prevention in atrial fibrillation, treatment of venous thromboembolism, and postoperative thromboprophylaxis in patients undergoing orthopedic surgery. DOACs are currently not approved for prevention of thrombosis in patients with acute medical illness, heart failure,
peripheral arterial disease, mechanical heart valves or other medical devices. DOAC trials are ongoing for many of these indications. Rivaroxaban is approved in Europe but not in the U.S. for patients with acute coronary syndromes. The use of fixed dose DOACs can be challenging in patients with very low or high body weight. 28 Because they are taken in fixed rather than weightadjusted doses, there is a potential concern that DOACs may not reach adequate blood levels in patients with severe obesity. Studies in healthy volunteers suggest that obesity has only modest effects on the pharmacokinetic profile of dabigatran, rivaroxaban, or apixaban and that dose adjustments for obesity may not be necessary. 29 For thromboprophylaxis after orthopedic surgery, a meta-analysis found similar efficacy and safety of DOACs in elderly obese and nonobese patients. 30 A meta-analysis of the major DOAC trials for treatment of VTE found no difference in efficacy or major bleeding between subgroups of patients with body weight < 100 Recommendations include early ambulation and lower extremity compression (elastic stockings, graduated compression stockings, and/or intermittent pneumatic compression) for all patients.
In addition, pharmacological prophylaxis is recommended for most patients, unless the bleeding risk is judged to be excessive. LMWH is generally preferred over unfractionated heparin, although studies comparing LMWH to unfractionated heparin have not been conclusive. 36 Warfarin is not recommended, and DOACs have not yet been studied for this indication. Optimal prophylactic dosing of LMWH for thromboprophylaxis for bariatric surgery is not known. Most published studies have employed empric LMWH dose adjustments, such as 150% of standard prophylactic doses, given in either fixed or weight-adjusted regimens. A meta-analysis did not demonstrate a significant difference in the efficacy or safety between adjusted-dose vs.
nonadjusted-dose LMWH. 38 Because of the substational risk of late (post hospital discharge) VTE, continuing prophylaxis with LMWH for at least 10 days following hospital discharge may be beneficial.
The use of inferior vena caval filters (VCFs) for prevention of PE in bariatric surgery has been evaluated in several studies, most of which were retrospective or registry studies with many
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From differences between the VCF and non-VCF groups that likely confounded the findings. 39 Some of these studies found higher rates of DVT but similar rates of PE in the VCF groups, which might suggest a possible benefit of VCFs in preventing PE in high risk patients. Alternatively, the higher rates of DVT might indicate that VCFs increase the risk of post-operative lower extremity venous thrombosis. Two systematic reviews with meta-analysis concluded that VCFs do not appear to decrease the risk of PE. 40, 41 Complications of VCFs include strut fracture, filter misplacement or migration, IVC perforation, arteriovenous fistula formation, infection, and failure to retrieve the filter with subsequent increased risk of future DVT. In summary, the currently available data do not support the routine use of VCFs in bariatric surgery.
Inflammatory bowel disease
Like obesity, IBD confers an increased risk of thrombosis. A meta-analysis of three large population-based retrospective studies revealed a 2.8-fold increased relative risk of a first episode of VTE in patients with IBD 42 ( Figure 1B) . The thrombotic risk is higher during flares of active disease than during remission. 43 The relative risk of VTE appears to be similar for
Crohn's disease and ulcerative colitis. IBD confers a 2.5-fold increased risk of recurrent VTE, which is similar to that of obesity and many other risk factors (Figure 2) . 44 IBD is also a risk factor for intra-abdominal (splanchnic) thrombosis of the portal, splenic, and mesenteric veins, especially in the perioperative setting, 42 and appears to be associated with increased risk of arterial thromboembolic events such as myocardial infarction and stroke. 45 
Mechanisms of thrombosis in IBD
The major mechanisms by which IBD drives thrombosis are illustrated in literature review of studies of VTE in IBD patients. 42 The authors were able to reach a clear consensus (60 to 100% agreement) despite the fact that most of the statements were supported only by low-quality evidence. Their recommendations include the use of anticoagulant thromboprophylaxis with either LMWH, unfractionated heparin, or fondaparinux for hospitalized medical or surgical patients with IBD in remission or with active flares of IBD without major gastrointestinal bleeding. For IBD patients undergoing major surgery, the risk of VTE in the absence of prophylaxis was estimated to be 3 to 6%, which corresponds to a moderate to high risk using the modified Caprini risk assessment model. 20 It is noteworthy that the recommendation for anticoagulant thromboprophylaxis includes patients with active IBD and minor gastrointestinal bleeding, despite the fact that gastrointestinal bleeding of any severity is
often considered to be an absolute contraindication to anticoagulant therapy. The safety of anticoagulant therapy in this setting is supported by a retrospective study of hospitalized IBD patients with minor rectal bleeding who received anticoagulant thromboprophylaxis without progression to major bleeding. 47 For IBD patients hospitalized with major gastrointestinal bleeding, mechanical thromboprophylaxis (graduated compression stockings, and/or intermittent pneumatic compression) is suggested. 42 Anticoagulant prophylaxis is not recommended for outpatients with flares of active IBD with no previous history of VTE, a recommendation that is similar to patients with obesity or other VTE risk factors. For outpatients with a previous episode of VTE, however, preventive anticoagulation is suggested during episodes of active IBD.
For patients with clinically inactive IBD who present with VTE associated with a provoking factor other than IBD, the recommended duration of anticoagulant therapy is a minimum of 3 months, with continuing therapy until one month after resolution of the provoking factor. 42 For IBD patients with unprovoked VTE presenting during clinical remission of IBD, indefinite anticoagulant therapy is recommended. Patients who present with a first episode of otherwise unprovoked VTE in the setting of an active flare of IBD, an extended duration of anticoagulant therapy is suggested, to continue until the IBD has been in remission for at least 3 months.
Whether or not to continue anticoagulation indefinitely after the IBD enters a remission phase is a challenging dilemma for clinicians, since insufficient data are available to determine thrombotic risk during remission and reliable biomarkers of IBD activity are lacking. Flares of disease activity are typically diagnosed clinically and by endoscopic biopsy rather than by measurement of laboratory parameters. Currently available non-invasive biomarkers of disease activity such as leukocytosis, erythrocyte sedimentation rate, and C-reactive protein lack both sensitivity and specificity. Thus, there is a need for better biomarkers to assessing IBD activity and the potential need for thromboprophylaxis. Calprotectin (S100A8/S100A9) is an inflammatory protein complex that is released into the feces by activated neutrophils and may 
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